Recent Updates
Recently added Catalysts

NTX/BUP

Phase 3

Opioid Use Disorder | Small molecule | Pain |Alkermes plc|Last Updated: Mar 6, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment380
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02537574Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)PHASE3 COMPLETED 380Aug 1, 2015Jan 9, 2017Mar 6, 201920 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Proportion of Subjects Who Receive and Tolerate a VIVITROL Injection
1 week

Toleration to the injection was demonstrated by mild opioid withdrawal symptoms (Clinical Opiate Withdrawal Scale \[COWS\] \</=12 or Subjective Opiate Withdrawal Scale \[SOWS\] \</=10) following VIVITROL administration. The COWS is a clinician-rated questionnaire designed to measure 11 common opioid withdrawal signs or symptoms. The summed score provides information about the level of physical dependence on opioids. The range of COWS scores is 0-4 (none to minimal); 5-12 (mild); 13-24 (moderate); 25-36 (moderately severe); and 37-48 (severe withdrawal. The SOWS is a 16-item self-report questionnaire designed to measure the severity of opioid withdrawal symptoms. The subject rates the intensity of symptoms using a 5-point scale. The range of SOWS scores is 1-10 (mild); 11-20 (moderate); and 21-30 (severe).

Secondary Endpoints
Proportion of Days With COWS Peak Score of Less Than or Equal to 12 During the Treatment Period Prior to the VIVITROL Injection
1 week
Mean Peak COWS Score During Treatment Period Prior to VIVITROL Injection
1 week
Area Under the Curve (AUC) COWS Score During the Treatment Period Prior to VIVITROL Injection
The COWS was administered 4-6 times per day during the Treatment Period (Days 1-7)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
NTX/BUPEXPERIMENTALOral naltrexone + sublingual buprenorphine
NTX/PBO-BACTIVE_COMPARATOROral naltrexone + sublingual placebo
PBO-N/PBO-BPLACEBO_COMPARATOROral placebo naltrexone + sublingual placebo buprenorphine
Interventions
NameTypeDescription
NTX/BUPDRUGDaily doses
NTX/PBO-BDRUGDaily doses
PBO-N/PBO-BDRUGDaily doses
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 60 Years
SexALL
Healthy VolunteersNo
Study Sites20

Inclusion Criteria: * Willing and able to provide informed consent * Willing and able to provide government-issued identification * Has a BMI of 18.0-40.0 kg/m\^2 * Has a physiologic dependence on opioids * Is voluntarily seeking treatment for opioid use disorder and willing to completely withdraw ...

Countries:United States
Unlock Eligibility Criteria